Effects of direct lung dosing of Tobramycin in a rat chronic infection model using Pseudomonas aeruginosa RP73

Gandi, Senthil Kumar; Cranston, Islay; McLachlan, Gerry; Wright, Steven H.; Baily, James; Stimpson, Susanna; Madden, Stephen F.; Whitmarsh, Mark; Young, Alan G.; McElroy, Mary C.

doi:10.1183/13993003.congress-2018.pa2656

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has recently been reported that the direct lung dosing of TOB at 3 mg/kg resulted in a significant reduction of CFU count in a similar rat PA chronic lung infection model. 43 However, that study used a very different treatment regimen by dosing the animals once daily via the oropharyngeal route from day -1 to 4 postinfection, and CFUs were counted from samples collected on day 4. In addition, the study also collected bronchoalveolar lavage fluid from the lung samples for CFU counts, making direct comparison of bacterial counts in the lung samples difficult.…”

Section: Discussionmentioning

confidence: 99%

“…In the efficacy studies, the range of doses used resulted in comparable CFU counts, suggesting that the lowest dose used (10 mg/kg) had likely already reached the maximum achievable effect at the endpoint of the study. It has recently been reported that the direct lung dosing of TOB at 3 mg/kg resulted in a significant reduction of CFU count in a similar rat PA chronic lung infection model . However, that study used a very different treatment regimen by dosing the animals once daily via the oropharyngeal route from day -1 to 4 postinfection, and CFUs were counted from samples collected on day 4.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Model-Informed Drug Development in Pulmonary Delivery: Semimechanistic Pharmacokinetic–Pharmacodynamic Modeling for Evaluation of Treatments against Chronic Pseudomonas aeruginosa Lung Infections

et al. 2020

View full text Add to dashboard Cite

Antibiotic resistance is a major public health threat worldwide, and among others, about 80% of cystic fibrosis patients have chronic Pseudomonas aeruginosa (PA) lung infection resistant to many current antibiotics. Novel treatment strategies are therefore urgently needed. For lung infections, direct delivery of treatments to the site of action in the airway can achieve a higher local concentration with minimal systemic exposure and hence avoid risks of unwanted systemic adverse effects. Previously, a rat preclinical disease model for PA chronic lung infections has been reported. However, the role of this disease model in the development of new treatment has not been thoroughly evaluated. In this study, tobramycin (TOB) was used as a model antibiotic to evaluate the application of this preclinical disease model for PA treatments. The obtained data were used for pharmacokinetic−pharmacodynamic (PKPD) modeling. Plasma samples following pulmonary delivery of TOB via different dosing methods as well as growth and efficacy data from the chronic lung infection disease model following TOB treatments were collected for analysis and modeling. The developed PKPD model incorporates a semimechanistic description on biofilm development in chronic infections to allow the evaluation of drug action on bacteria in different states (i.e., planktonic, biofilm, and latent) and describes the available data from the efficacy study. The PKPD model can be used to support the application of the preclinical lung infection disease model by providing a quantitative description of the drug exposure−response relationship and a mechanistic platform to integrate all available PK and PKPD data with predictive capacity. With the support of appropriate experimental designs, the model can be further extended for other applications to, for instance, study the transition of bacteria between states and describe drug actions on biofilms.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%